HITS raises ₩18.3B for an AI co-scientist

South Korean drug-discovery company HITS closed an ₩18.3 billion Series B, ChosunBiz reports. The company plans to launch HyperLab Co-Scientist in November 2026, with autonomous-lab integration targeted for 2027; HyperLab’s product page describes a platform for screening and designing drug candidates. For scientific-AI builders, this is a roadmap signal rather than validated autonomy: compare benchmark claims with reproducible wet-lab outcomes, as the archive’s analysis of AI drug-discovery systems argues.